JP7720307B2 - 操作されたＬｅｉｓｈｍａｎｉａ細胞 - Google Patents

操作されたＬｅｉｓｈｍａｎｉａ細胞

Info

Publication number
JP7720307B2
JP7720307B2 JP2022541861A JP2022541861A JP7720307B2 JP 7720307 B2 JP7720307 B2 JP 7720307B2 JP 2022541861 A JP2022541861 A JP 2022541861A JP 2022541861 A JP2022541861 A JP 2022541861A JP 7720307 B2 JP7720307 B2 JP 7720307B2
Authority
JP
Japan
Prior art keywords
nucleotides
dna fragments
homologous
leishmania
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022541861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509734A5 (https=
JP2023509734A (ja
Inventor
マリー マヌエラ
ファリドモアイエル アミルレザ
セルベンティ ファビオ
フォラドール レイナー
ジュディス ハーズマン アンケ
Original Assignee
リンマテック バイオロジクス エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リンマテック バイオロジクス エージー filed Critical リンマテック バイオロジクス エージー
Publication of JP2023509734A publication Critical patent/JP2023509734A/ja
Publication of JP2023509734A5 publication Critical patent/JP2023509734A5/ja
Application granted granted Critical
Publication of JP7720307B2 publication Critical patent/JP7720307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022541861A 2020-01-07 2021-01-07 操作されたＬｅｉｓｈｍａｎｉａ細胞 Active JP7720307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958088P 2020-01-07 2020-01-07
US62/958,088 2020-01-07
PCT/EP2021/050173 WO2021140144A1 (en) 2020-01-07 2021-01-07 Engineered leishmania cells

Publications (3)

Publication Number Publication Date
JP2023509734A JP2023509734A (ja) 2023-03-09
JP2023509734A5 JP2023509734A5 (https=) 2024-01-23
JP7720307B2 true JP7720307B2 (ja) 2025-08-07

Family

ID=74194706

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022541861A Active JP7720307B2 (ja) 2020-01-07 2021-01-07 操作されたＬｅｉｓｈｍａｎｉａ細胞

Country Status (6)

Country Link
US (1) US20230048847A1 (https=)
EP (1) EP4087912A1 (https=)
JP (1) JP7720307B2 (https=)
AU (1) AU2021206008A1 (https=)
CA (1) CA3166728A1 (https=)
WO (1) WO2021140144A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240145084A (ko) 2017-06-30 2024-10-04 림마테크 바이오로직스 아게 조작되고 완전-기능 맞춤 당단백질
JP2024513755A (ja) 2021-03-23 2024-03-27 グリコエラ アーゲー マンノース３グリカン媒介タンパク質分解
WO2022200390A2 (en) 2021-03-23 2022-09-29 Glycoera Ag Glycan-mediated protein degradation
WO2024068753A1 (en) 2022-09-28 2024-04-04 Glycoera Ag Glycan-mediated protein degradation
US20260055211A1 (en) 2023-01-05 2026-02-26 Glycoera Ag Glycoengineered polypeptides targeting anti-neutrophil autoantibodies and uses thereof
WO2024147113A1 (en) 2023-01-05 2024-07-11 Glycoera Ag Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof
JP2026501773A (ja) 2023-01-05 2026-01-16 グリコエラ アーゲー 免疫グロブリンａを標的とする糖鎖改変ポリペプチド及びそれを含む複合体
WO2024218743A1 (en) 2023-04-21 2024-10-24 Glycoera Ag Multi-functional molecules comprising glycans and uses thereof
WO2025215516A1 (en) 2024-04-08 2025-10-16 Glycoera Ag Glycoengineered polypeptides targeting igg4 autoantibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539836A (ja) 1999-03-26 2002-11-26 ワシントン・ユニバーシティ 原生動物発現系
JP2003513632A (ja) 1999-11-05 2003-04-15 イェーナ・バイオサイエンス・ゲーエムベーハー 非病原性キネトプラスチダエのタンパク質発現システム
JP2014519831A (ja) 2011-06-21 2014-08-21 エヴィアジェニクス ソシエテ・アノニム 代謝的進化の方法
WO2019002512A2 (en) 2017-06-30 2019-01-03 Limmatech Biologics Ag GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
JP2019516378A (ja) 2016-05-18 2019-06-20 アミリス， インコーポレイテッド 外因性ランディングパッドへの核酸のゲノム組込みのための組成物および方法
WO2019234021A1 (en) 2018-06-04 2019-12-12 Limmatech Biologics Ag Glycoengineered monoclonal antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133557D1 (de) * 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
WO2002090556A1 (en) * 2001-05-08 2002-11-14 Jena Bioscience Gmbh Method for targeted homologous gene replacement in kinetoplastidae

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002539836A (ja) 1999-03-26 2002-11-26 ワシントン・ユニバーシティ 原生動物発現系
JP2003513632A (ja) 1999-11-05 2003-04-15 イェーナ・バイオサイエンス・ゲーエムベーハー 非病原性キネトプラスチダエのタンパク質発現システム
JP2014519831A (ja) 2011-06-21 2014-08-21 エヴィアジェニクス ソシエテ・アノニム 代謝的進化の方法
JP2019516378A (ja) 2016-05-18 2019-06-20 アミリス， インコーポレイテッド 外因性ランディングパッドへの核酸のゲノム組込みのための組成物および方法
WO2019002512A2 (en) 2017-06-30 2019-01-03 Limmatech Biologics Ag GLYCOPROTEINS CUSTOMIZED FROM ENGINEERING AND FULLY FUNCTIONAL
WO2019234021A1 (en) 2018-06-04 2019-12-12 Limmatech Biologics Ag Glycoengineered monoclonal antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nucleic Acids Research，2009年，Vol.37, No.2，e16 (pp.1-10)

Also Published As

Publication number Publication date
US20230048847A1 (en) 2023-02-16
EP4087912A1 (en) 2022-11-16
CA3166728A1 (en) 2021-07-15
AU2021206008A1 (en) 2022-07-28
WO2021140144A1 (en) 2021-07-15
JP2023509734A (ja) 2023-03-09

Similar Documents

Publication Publication Date Title
JP7720307B2 (ja) 操作されたＬｅｉｓｈｍａｎｉａ細胞
JP7684310B2 (ja) Ｌｅｉｓｈｍａｎｉａ細胞を使用する糖鎖修飾改変
JP7437162B2 (ja) 改変されかつ完全に機能カスタマイズされた糖タンパク質
US20200002727A1 (en) Multi-site specific integration cells for difficult to express proteins
WO2024068768A1 (en) Glycoengineering using leishmania cells
US20220049275A1 (en) Ssi cells with predictable and stable transgene expression and methods of formation
CN108779443A (zh) 产生糖基化蛋白的方法
US20230056404A1 (en) Systems and methods for protein expression
US20250018024A1 (en) Compositions and methods for protein expression with rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250728

R150 Certificate of patent or registration of utility model

Ref document number: 7720307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150